Year | 2015 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|---|
No. of antimicrobials | |||||
Type of indication | 768 | 755 | 839 | 821 | 780 |
Community acquired infections | 482 (63%) | 353 (47%) | 500 (60%) | 487 (59%) | 444 (57%) |
Healthcare associated infection | 227 (30%) | 295 (39%) | 245 (29%) | 212 (26%) | 247 (32%) |
Medical prophylaxis | 8 (1%) | 30 (4%) | 37 (4%) | 35 (4%) | 42 (5%) |
Surgical prophylaxis | 36 (5%) | 34 (5%) | 26 (3%) | 26 (3%) | 27 (4%) |
Unknown indication | 13 (2%) | 39 (5%) | 23 (3%) | 28 (3%) | 13 (2%) |
Others (e.g. use as prokinetic) | 2 (< 1%) | 4 (1%) | 8 (1%) | 33 (4%) | 7 (1%) |
No. of patients | |||||
Top 10 diagnosis | 550 | 504 | 562 | 550 | 501 |
Pneumonia or lower respiratory tract infection | 184 (34%) | 142 (29%) | 144 (26%) | 150 (27%) | 144 (29%) |
Skin and soft tissue infections† | 81 (15%) | 54 (11%) | 61 (11%) | 75 (14%) | 66 (13%) |
Intra-abdominal infections‡ | 54 (10%) | 47 (9%) | 55 (10%) | 49 (9%) | 44 (9%) |
Upper urinary tract infections§ | 28 (5%) | 14 (3%) | 61 (11%) | 48 (9%) | 65 (13%) |
Lower urinary tract infections (cystitis) | 44 (8%) | 58 (12%) | 44 (8%) | 36 (7%) | 20 (4%) |
Gastrointestinal infections | 16 (3%) | 23 (5%) | 21 (4%) | 24 (4%) | 21 (4%) |
Unknown | 8 (2%) | 36 (7%) | 26 (5%) | 21 (4%) | 10 (2%) |
Bone and joint infections** | 12 (2%) | 14 (3%) | 19 (3%) | 22 (4%) | 17 (3%) |
Acute Bronchitis or exacerbations of chronic bronchitis | 10 (2%) | 15 (3%) | 17 (3%) | 17 (3%) | 6 (1%) |
Sepsis†† | 19 (4%) | 23 (5%) | 12 (2%) | 15 (3%) | 8 (2%) |